{"prompt": "['Product: MK-3475', '136', 'Protocol/Amendment No.: 604-09', 'III. Subject Protection', 'A. IRB/ERC review', 'All clinical trials will be reviewed and approved by an independent IRB/ERC before being initiated at each site.', 'Significant changes or revisions to the protocol will be approved by the IRB/ERC prior to implementation, except that', 'changes required urgently to protect subject safety and well-being may be enacted in anticipation of IRB/ERC', 'approval. For each site, the IRB/ERC and Merk will approve the subject informed consent form.', 'B. Safety', 'The guiding principle in decision-making in clinical trials is that subject welfare is of primary importance. Potential', 'subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial', 'designs will take into account the local standard of care. Subjects are never denied access to appropriate medical care', 'based on participation in a Merk clinical trial.', 'All participation in Merk clinical trials is voluntary. Subjects are enrolled only after providing informed consent for', 'participation. Subjects may withdraw from a Merk trial at any time, without any influence on their access to, or', 'receipt of, medical care that may otherwise be available to them.', 'C. Confidentiality', 'Merk is committed to safeguarding subject confidentiality, to the greatest extent possible. Unless required by law,', 'only the investigator, Sponsor (or representative) and/or regulatory authorities will have access to confidential medical', 'records that might identify the research subject by name.', 'D. Genomic Research', 'Genomic Research will only be conducted in accordance with informed consent and/or as specifically authorized by', 'an Ethics Committee.', 'IV. Financial Considerations', 'A. Payments to Investigators', \"Clinical trials are time- and labor-intensive. It is Merck's policy to compensate investigators (or the sponsoring\", 'institution) in a fair manner for the work performed in support of Merk trials. Merk does not pay incentives to', 'enroll subjects in its trials. However, when enrollment is particularly challenging, additional payments may be made', 'to compensate for the time spent in extra recruiting efforts.', 'Merk does not pay for subject referrals. However, Merk may compensate referring physicians for time spent on', 'chart review to identify potentially eligible subjects.', 'B. Clinical Research Funding', 'Informed consent forms will disclose that the trial is sponsored by Merkk, and that the investigator or sponsoring', 'institution is being paid or provided a grant for performing the trial. However, the local IRB/ERC may wish to alter', 'the wording of the disclosure statement to be consistent with financial practices at that institution. As noted above,', 'publications resulting from Merk trials will indicate Merk as a source of funding.', 'C. Funding for Travel and Other Requests', 'Funding of travel by investigators and support staff (e.g., to scientific meetings, investigator meetings, etc.) will be', 'consistent with local guidelines and practices including, in the U.S., those established by the American Medical', 'Association (AMA).', 'V. Investigator Commitment', \"Investigators will be expected to review Merck's Code of Conduct as an appendix to the trial protocol, and in signing\", 'the protocol, agree to support these ethical and scientific standards.', '* In this document, \"Merck\" refers to Merk Sharp & Dohme Corp. and Schering Corporation, each of which is a', 'subsidiary of Merk & Co., Inc. Merk is known as MSD outside of the United States and Canada. As warranted by', 'context, Merk also includes affiliates and subsidiaries of Merk & Co., Inc.\"', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '137', 'Protocol/Amendment No.: 604-09', '12.2 Collection and Management of Specimens for Future Biomedical Research', '1. Definitions', 'a.', 'Biomarker: A biological molecule found in blood, other body fluids, or tissues that is', 'a sign of a normal or abnormal process or of a condition or disease. A biomarker may', 'be used to see how well the body responds to a treatment for a disease or condition. 1', 'b. Pharmacogenomics: The investigation of variations of DNA and RNA characteristics', 'as related to drug response.2', 'c.', 'Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the', 'influence of variations in DNA sequence on drug response.2', 'd. DNA: Deoxyribonucleic acid.', 'e.', 'RNA: Ribonucleic acid.', '2. Scope of Future Biomedical Research', 'The specimens consented and/or collected in this trial as outlined in Section 7.1.3.4 will', 'be used in various experiments to understand:', 'The biology of how drugs work', 'Biomarkers responsible for how a drug enters and is removed by the body', 'Other pathways drugs may interact with', 'The biology of disease', 'The specimen(s) may be used for future assay development and/or drug/vaccine', 'development.', 'It is now well recognized that information obtained from studying and testing clinical', 'specimens offers unique opportunities to enhance our understanding of how individuals', 'respond to drugs/vaccines, enhance our understanding of human disease and ultimately', 'improve public health through development of novel treatments targeted to populations', 'with the greatest need. All specimens will be used by the Sponsor or those working for', 'or with the Sponsor.', '3. Summary of Procedures for Future Biomedical Research', 'a. Subjects for Enrollment', 'All subjects enrolled in the clinical trial will be considered for enrollment in the', 'Future Biomedical Research sub-trial.', 'b. Informed Consent', 'Informed consent for specimens (i.e., DNA, RNA, protein, etc.) will be obtained', 'during screening for protocol enrollment from all subjects or legal guardians, at a trial', 'visit by the investigator or his or her designate. Informed consent for Future', 'Biomedical Research should be presented to the subjects on the visit designated in the', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}